Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Azelnidipine

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,185Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 5Rezaltas

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Rezaltas

    Azelnidipine

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Rezaltas

    Japan
    arrow
    BIOHK2025
    Not Confirmed

    Daiichi Sankyo

    Azelnidipine

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2020 Revenue in Millions : 123

    2019 Revenue in Millions : 137

    Growth (%) : -11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Rezaltas

    Azelnidipine

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Rezaltas

    Japan
    arrow
    BIOHK2025
    Not Confirmed

    Daiichi Sankyo

    Azelnidipine

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2021 Revenue in Millions : 104

    2020 Revenue in Millions : 122

    Growth (%) : -8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Rezaltas

    Olmesartan Medoxomil, Azelnidipine

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Rezaltas

    Japan
    arrow
    BIOHK2025
    Not Confirmed

    Daiichi Sankyo

    Olmesartan Medoxomil, Azelnidipine

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2017 Revenue in Millions : 170

    2016 Revenue in Millions : 163

    Growth (%) : 4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Rezaltas

    Olmesartan Medoxomil, Azelnidipine

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Rezaltas

    Japan
    arrow
    BIOHK2025
    Not Confirmed

    Daiichi Sankyo

    Olmesartan Medoxomil, Azelnidipine

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2018 Revenue in Millions : 143

    2017 Revenue in Millions : 159

    Growth (%) : -10%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Rezaltas

    Azelnidipine

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Rezaltas

    Japan
    arrow
    BIOHK2025
    Not Confirmed

    Daiichi Sankyo

    Azelnidipine

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2019 Revenue in Millions : 139

    2018 Revenue in Millions : 148

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF